The RET gene encodes a receptor tyrosine kinase whose function is essential during the development of kidney and the intestinal nervous system. Germline mutations aecting one of ®ve cysteines (Cys609, 611, 618, 620 and 634) located in the juxtamembrane domain of the RET receptor are responsible for the vast majority of two cancer-prone disorders, multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC). These mutations lead to the replacement of a cysteine by an alternate amino acid. Mutations of the RET gene are also the underlying genetic cause of Hirschsprung disease (HSCR), a congenital aganglionosis of the hindgut. In a fraction of kindreds, MEN 2A cosegregate with HSCR and aected individuals carry a single mutation at codons 609, 618 or 620. To examine the consequences of cysteine substitution on RET function, we have introduced a Cys to Arg mutation into the wild-type RET at either codons 609, 618, 620, 630 or 634. We now report that each mutation induces a constitutive catalytic activity due to the aberrant disul®de homodimerization of RET. However, mutations 630 and 634 activate RET more strongly than mutations 609, 618 or 620 as demonstrated by quantitative assays in rodent ®broblasts and pheochromocytoma PC12 cells. Biochemical analysis revealed that mutations 618 and 620, and to a lesser extent mutation 609, result in a marked reduction of the level of RET at the cell surface and as a consequence decrease the amount of RET covalent dimer. These ®ndings provide a molecular basis explaining the range of phenotype engendered by alterations of RET cysteines and suggest a novel mechanism whereby mutations of cysteines 609, 618 and 620 exert both activating and inactivating eects.
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Introduction
Mutations in the RET proto-oncogene, which encodes a transmembrane protein tyrosine kinase, cause two inherited neural crest disorders: multiple endocrine neoplasia type 2 (MEN 2) and Hirschsprung disease (HSCR). Recent studies have provided evidence that RET is a component of a multi-subunit complex which acts as a receptor for the Glial cell-line Derived Neurotrophic Factor (GDNF) and for neurturin, two homologous members of the transforming growth factor b (TGF-b) family (reviewed in Lindsay and Yancopoulos, 1996 . For references see Milbrandt et al., 1998) . GDNF and neurturin-binding require accessory receptors called GFRa-1 and GFRa-2 that associate with RET and are anchored to the plasma membrane via a glycosyl ± phosphatidylinositol linkage (reviewed in Lindsay and Yancopoulos, 1996 . For references see Milbrandt et al., 1998) . Mice homozygous for a disruptive mutation either in the RET or the GDNF gene show renal agenesis or dysgenesis of the kidneys and lack the intestinal nervous system (reviewed in Lindsay and Yancopoulos, 1996) . These results indicate that RET and GDNF play a critical role during renal organogenesis and are required for the development of a subset of vagal neural crest cells.
MEN 2 is a familial cancer syndrome with an autosomal dominant mode of inheritance and a high degree of penetrance. This syndrome is characterized by the development of bilateral and multicentric medullary thyroid carcinoma (MTC), a malignant tumor arising from calcitonin-secreting thyroid C cells. Three clinically related disorders have been recognized, MEN type 2A (MEN 2A) which associates MTC, pheochromocytoma (Pheo) and less frequently hyperplasia of the parathyroid glands; MEN type 2B (MEN 2B) that includes MTC, Pheo, oral neuromas, ganglioneuromatosis of the digestive tract and skeletal abnormalities and ®nally, familial MTC (FMTC) de®ned by the sole occurrence of MTC (reviewed in Mulligan and Ponder, 1995; Goodfellow and Wells, 1995; Pasini et al., 1996) . Allelic germline mutations of the RET proto-oncogene are responsible for the three MEN 2 variants (Donis-Keller et al., 1993; Mulligan et al., 1993; Carlson et al., 1994; Eng et al., 1994; Hofstra et al., 1994) and a recent survey of a large panel of MEN 2 families supports the existence of a correlation between the position and nature of the RET mutations and the clinical phenotype (Eng et al., 1996) . The vast majority of MEN2A and FMTC mutations aects one of six juxtamembrane cysteines (Cys 609, 611, 618, 620, 630 and 634) and these mutations result in the substitution of a cysteine for a dierent amino acid (Mulligan et al., 1994a; Schuffenecker et al., 1994; Eng et al., 1996; Frank-Raue et al., 1996) . However, mutations at codon specifying cysteine 634 occur in 85% of MEN 2A cases, whereas mutations causing FMTC are more evenly distributed among codons 618, 620 and 634 (Eng et al., 1996) . Alterations at codons 609 and 611 are less frequently found in MEN 2A or FMTC and germline mutation at codon 630 has been documented, so far, in only four patients with MTC (Komminoth et al., 1995; Kitamura et al., 1997) . Furthermore, missense mutations aecting one of ®ve distinct residues within the tyrosine kinase domain have been characterized in FMTC families and in a few MEN 2A families Bolino et al., 1995; Fink et al., 1996; Hofstra et al., 1997; Berndt et al., 1998) . Finally, the majority of MEN 2B cases is caused by a unique mutation (M918T) which lies in the RET catalytic domain (Carlson et al., 1994; Eng et al., 1994; Hofstra et al., 1994; Rossel et al., 1995) , although a distinct mutation located within the tyrosine kinase of RET (A883F) has been identi®ed in two de novo cases of MEN 2B . Experimental studies have demonstrated that MEN2 mutations confer an oncogenic potential to RET as a consequence of the ligand-independent constitutive tyrosine kinase activity Santoro et al., 1995) . The nature of the MEN2 mutations dictates the molecular mechanisms of RET activation. MEN2A and FMTC mutations involving cysteines promote RET homodimerization via the formation of intermolecular disul®de bonding Santoro et al., 1995) , while the MEN2B mutation appears to modify the substrate speci®city of the tyrosine kinase Songyang et al., 1995) .
HSCR is a common congenital malformation (1/ 5000 live births) characterized by the absence of enteric nervous plexuses in the hindgut, leading to intestinal obstruction in neonates or chronic severe constipation in adults (reviewed in Reynolds and Eng, 1995; Chakravarti, 1996) . Alterations in the RET locus have been identi®ed in familial and sporadic cases of HSCR (Edery et al., 1994; Romeo et al., 1994) . The nature of these mutations which include insertions, deletions, nonsense and missense mutations scattered throughout the coding sequence and the phenotype of the RET null mice, suggested that HSCR could be ascribed to a loss of RET function (reviewed in Reynolds and Chakravarti, 1996) . In agreement with this hypothesis, most of the HSCR missense mutations tested so far disable the RET function (Pasini et al., 1995; Carlomagno et al., 1996; Iwashita et al., 1996; Pelet et al., 1998) .
Although the association between speci®c MEN2 mutations and phenotype is well-documented, the comprehension of the underlying molecular mechanisms is still limited. We have recently demonstrated that mutations frequently found in FMTC are more weakly activating than mutations preferentially associated with MEN 2A, a ®nding which suggests that the broader spectrum of endocrine tissues aected in MEN 2A re¯ects the more potent transforming capacity of the RET mutants (Carlomagno et al., 1997; Pasini et al., 1997) . However, the observation that HSCR and MEN 2A cosegregate in a fraction of MEN 2A families and that these patients carry a single missense mutation at either codon 609, 618 or 620 with no evidence of other mutations in the RET coding sequence (Mulligan et al., 1994b; Borst et al., 1995; Blank et al., 1996; Caron et al., 1996; Eng et al., 1996; Decker et al., 1998) challenges the notion that MEN2 and HSCR mutations exert opposing eects on RET. We now report that mutations of cysteines 609, 618 and 620 cause disul®de-linked dimerization of RET but also result in a marked decrease of the level of the mature RET protein present at the plasma membrane. The dual eect of these mutations accounts for a weaker oncogenic capacity of RET bearing a mutation at cysteines 609, 618 or 620 compared with RET carrying a mutation at cysteine 630 or 634 and provides a coherent explanation for the relationships between genotype and disease phenotype.
Results

Graded activation of RET correlates with the position of mutations aecting extra-cytoplasmic cysteines
To compare the functional consequences of mutations aecting extra-cytoplasmic cysteines, we introduced individual mutations that lead to the substitution of cysteines 609, 618, 620, 630 or 634 for an arginine in the cDNA coding for the long RET isoform of 1114 amino acids (here referred to as RET51) (Figure 1 ). NIH3T3 ®broblasts were infected with recombinant ecotropic retroviruses expressing these various RET alleles and mass populations of puromycin-resistant cells were selected. Lysates prepared from NIH3T3 cells stably expressing RET wild-type or RET Cys mutants were immunoprecipitated with an anti-RET serum and the resulting immunocomplexes were analysed by SDS-polyacrylamide gel electrophoresis (PAGE). Western blotting of these samples with an anti-RET polyclonal antibody revealed two products of 150 kDa and 170 kDa (Figure 2 ). The 150 kDa product corresponds to an incompletely glycosylated form of RET, sensitive to the treatment with endoglycosidase H and present in the endoplasmic reticulum while the 170 kDa band is the mature RET protein, fully glycosylated and expressed at the cell surface (Taniguchi et al., 1991) . The dierent RET Cys mutants were correctly synthesized and comparable amounts of RET proteins were present in each lane. Probing of the same ®lter with the antiphosphotyrosine monoclonal antibody 4G10 revealed a net increase in the steady-state phosphotyrosine , RET Cys618 and RET Cys620 (Figure 2 ). Taken together, these data indicated that each of the ®ve cysteine substitutions resulted in activation of RET enzymatic activity. To ascertain that RET Cys mutants were constitutively active, we next examined the tyrosine phosphorylation of Shc proteins which bind to and are downstream targets of several receptor tyrosine kinases, including RET (van Weering et al., 1995; Asai et al., 1996; Arighi et al., 1997; Lorenzo et al., 1997) . Cell lysates were prepared from NIH3T3 cells stably expressing comparable levels of either RET wild-type or the various RET Cys mutants and the Shc proteins were analysed by immunoprecipitation and Western blotting with a polyclonal serum recognizing Shc. Figure 3 Cys mutants. Samples were fractionated on a SDS ± 8% polyacrylamide gel, transferred on membrane, incubated with the monoclonal antibody antiphosphotyrosine 4G10 followed by addition of horse-radish peroxydase conjugated-secondary antibody and revealed using the ECL system (upper panel). The ®lter was stripped and reprobed with the anti-RET polyclonal serum (lower panel). The two RET species of 150 kDa and 170 kDa are indicated 
Aberrant covalent dimerization of RET Cys mutants
It was previously demonstrated that ligand-independent activation of RET Cys620 and RET Cys634 is mediated through the formation of disul®de-linked RET homodimer Santoro et al., 1995; Carlomagno et al., 1997) . Since mutations at cysteines 609, 618 and 630 result in the constitutive stimulation of the RET catalytic activity, it was likely that these mutations could act through a similar mechanism. To test this hypothesis, we looked for the presence of RET disul®de-linked homodimers in cells transduced with retroviruses expressing RET wild-type or RET Cys mutants. Total cellular lysates prepared from NIH3T3 cells stably expressing RET were fractionated by SDS ± PAGE under non reducing conditions and analysed by Western blot with an anti-RET antibody.
Under these conditions, a band of an apparent molecular weight of 340 kDa with the size of a disul®de-linked homodimer, was present in lysates prepared from NIH3T3 cells expressing RET Cys634 (Figure 4a ). The band at 340 kDa corresponding to the RET homodimer was speci®c to RET Cys mutants, since this product was not detectable in cells expressing either RET wild-type or a mutant form of RET bearing an activating FMTC mutation which changes valine 804 for a leucine within the tyrosine kinase domain (Figure 4a) .
We next used an in vitro immunokinase assay, since this technique has been reported to be more sensitive than Western blotting for the detection of RET homodimer (Wada et al., 1996) . NIH3T3 cells expressing the dierent RET alleles were lysed in a buer containing 10 mM iodoacetamide (IAA). IAA was added to alkylate free thiol groups in order to prevent artefactual covalent dimerization due to the aggregation of RET molecules in the immune complex. Equal amounts of RET proteins were immunoprecipitated with the anti-RET serum and the resulting complexes were subjected to in vitro kinase assay in presence of [g Figure 4b ). In summary, these results indicate that mutations at each one of the ®ve cysteines considered in this study lead to the formation of the RET disul®de-linked homodimer. Furthermore, the level of covalent dimer formed by RET Cys609 , RET Cys618 and RET Cys620 is drastically lower than that for the other RET Cys mutants.
Decreased cell surface expression of RET carrying mutations at Cys609, 618 or 620
Asai and coworkers have provided evidence that the RET covalent dimer is composed of two 170 kDa RET species , thus suggesting that the dimer is mostly formed at the cell surface. Therefore, two explanations, not mutually exclusive, might account for the reduced level of covalent dimer formed by RET
Cys618
, RET
Cys620
, and to a lesser extent RET Cys609 , compared to RET Cys630 and RET
Cys634
. Firstly, mutations of Cys-609, 618 and 620 might impede the disul®de-bonding of two adjacent RET molecules due to steric hindrance. Secondly, these mutations might result in a decrease of the level of RET at the cell surface, either by altering its overall stability or by inhibiting its transport to the plasma membrane. The latter explanation was appealing because such an eect has been ascribed to HSCR mutations mapping in the extracytoplasmic domain of RET (Carlomagno et al., 1996; Iwashita et al., 1996) . To test this hypothesis, we examined the respective amount of the 170 kDa and the 150 kDa RET species on a SDS ± 8% polyacrylamide gel, allowing a better resolution of these two bands. As shown in Figure 5a , the amount of the Cys mutants were lysed in a buer containing 10 mM iodoacetamide and immunoprecipitated with an anti-RET serum. Iodoacetamide was added in order to prevent covalent dimerization of RET through artefactual bridging of free thiol groups. The immunoprecipitates were then subjected to an in vitro kinase assay using [ (Figure 5b ). Quanti®cation by densitometry of two independent experiments revealed that the amount of the 170 kDa species was approximately 2 ± 2.5-fold lower for RET Cys618 and RET Cys620 and 1.5-fold lower for RET Cys609 compared to RET wild-type or RET
. Reprobing the ®lters with streptavidin-conjugated horseradish peroxydase con®rmed that these results were not explained by a dierence in the eciency of biotinylation of the dierent cell lines (data not shown).
Transforming activities of RET Cys mutants
We next compared the transforming eciency of the RET Cys mutants in NIH3T3 cells. Transformed foci were scored 14 days after transfection. 
Quantitative eects of RET Cys mutants in PC12 cells
We have recently set up an experimental system which allows to quantitate the eects mediated by oncogenic forms of RET (Califano et al., 1996) . This system is based on the observation that activated forms of RET stimulate the transcription of genes implicated in the neuronal dierentiation of the rat pheochromocytoma PC12 cell line. In this study, we have assayed the respective capacity of the various RET Cys mutants at inducing the transcription of the chloramphenicol acetyl transferase (CAT) reporter gene driven either by the NFGI-A or by the vgf promoter. NGFI-A and vgf are respectively immediate-early and delayed response genes whose expression is rapidly turned on upon treatment of PC12 cells with nerve growth factor (NGF) (JanssenTimmen et al., 1989; Possenti et al., 1992) . As ( Figure 6b ). The eects exhibited by RET Cys mutants on NGFI-A and vgf promoters were speci®c since no stimulation of CAT activity was observed when the Rous Sarcoma virus promoter fused to the CAT gene was used as a reporter (data not shown). Taken together, these data provide compelling evidence that RET Cys mutants are constitutively activated receptors capable to trigger neuronal dierentiation pathways in PC12 cells. Furthermore, quantitative analyses in PC12 cells con®rm the correlation between the position of the mutated cysteine and the strength of the biological response evoked by the activated RET receptor.
Discussion
The intent of the present work was to explore the functional consequences of MEN2A and FMTC mutations aecting juxtamembrane cysteines of the RET receptor. Point mutations which result in the substitution of cysteines 609, 618, 620, 630 or 634 for an arginine were introduced into one RET isoform. Results reported herein demonstrate that the ®ve RET Cys mutant receptors were constitutively active as manifested by their enhanced tyrosine autophosphorylation and their ability to phosphorylate downstream target eectors. The activation of RET and the ensuing transduction of a ligand-independent signaling was mediated through the formation of aberrant disul®de-bridged RET homodimer. Consistent with these ®ndings, the RET Cys mutants were transforming in rodent ®broblasts and induced expression of genes involved in neuronal dierentiation of PC12 cells. However, the degree of activation of RET Cys609 , RET Cys618 and RET Cys620 was signi®cantly lower than that of RET Cys630 or RET Cys634 as evidenced by the reduced biological activity of former RET mutants. Following this line of investigation, we showed that mutations of Cys609, Cys618 or Cys620 resulted in a decrease of the level of the RET protein present at the cell surface compared to RET wild-type and other RET Cys mutants, hence leading to a lower abundance of the constitutively active RET covalent dimer.
Consistent with a previous study (Carlomagno et al., 1997) , we have found that mutations more frequently associated with FMTC and aecting cysteines 609, 618 or 620 are weakly activating compared to mutations of Cys634 which are found in more than 85% of MEN 2A cases (Eng et al., 1996) . These results suggest that the higher transforming activity of RET Cys634 mutant compared to other RET Cys mutants underlie the broader range of endocrine phenotype which characterizes MEN 2A versus FMTC. This model aptly accounts for the milder course of the disease in terms of cure rate and life expectancy in families with a Cys618 mutation versus families with a Cys634 mutation (Moers et al., 1996) . Further support to this hypothesis comes from our recent observation that mutations E768D and V804L, so far reported only in FMTC families, lead to a much weaker RET activation than mutation of Cys634 . Mutation at codon 630 occurs rarely and has been described in the germline of four patients with MTC (Komminoth et al., 1995; Kitamura et al., 1997) . Also, a six basepair deletion which removes Cys630 and a missense mutation which changes Cys630 for an arginine have been described in sporadic MTCs (Donis-Keller et al., 1993; Bugalho et al., 1997) . Consistent with these observations, our data demonstrate that alteration of Cys630 is an activating mutation which leads to a constitutive stimulation of the RET receptor.
Substitution of Cys609, Cys618 or Cys620 for an arginine provoked a drastic reduction of the number of cell surface RET receptors. A similar eect has been observed with RET carrying a mutation that changes Cys620 for a tyrosine (Carlomagno et al., 1997) , thus suggesting that the position and not the nature of the causative mutation is the critical factor. What are the underlying molecular mechanisms which might explain this phenomenon? One plausible explanation for this eect is that mutations of Cys609, Cys618 or Cys620 and not of Cys630 or Cys634 would disrupt the intracellular tracking of RET. For instance, it is known that exposed thiol groups in immunoglobulins result in a cytoplasmic retention of unassembled molecules through the formation of disul®de-bonds with proteins of the endoplasmic reticulum (see references in Isidoro et al., 1996) . A similar argument could be brought forward if mutations of Cys609, Cys618 or Cys620 would free a cysteine more accessible to the reticulum environment than the partners of Cys630 or Cys634. Alternatively, alterations of Cys609, Cys618 or Cys620 might render the cell surface RET protein more sensitive to the action of proteases, hence preventing its stable expression at the plasma membrane. Future work should yield insight into the molecular basis of the dual eect of these RET mutations.
According to a recent study, the HSCR phenotype is a more frequent occurrence in MEN 2A families than initially anticipated (Decker et al., 1998) . So far, all families in which MEN 2A and HSCR are associated have been screened for mutations at the RET locus and these studies have revealed either a mutation at codon 609, 618 or at codon 620 (Mulligan et al., 1994b; Borst et al., 1995; Blank et al., 1996; Caron et al., 1996; Eng et al., 1996; Decker et al., 1998) . In these kindreds the RET mutation was shown to segregate with both traits and analysis of the entire RET coding sequence failed to identify a second mutation (Mulligan et al., 1994b; Borst et al., 1995; Blank et al., 1996; Caron et al., 1996; Eng et al., 1996) . These observations were at odds with the notion that MEN2A and HSCR mutations exert opposing eects on RET function and several explanations were proposed to unravel this paradox, including a second distinct mutation within the RET locus, the action of modi®er genes, a multihit mechanism or the selective activation of apoptotic programmes in enteric neuroblasts (Mulligan et al., 1994b; Borst et al., 1995; Blank et al., 1996; Pasini et al., 1996) . The ®nding that mutations at Cys609, 618 or 620 lead to a decrease in the amount of the mature RET protein expressed at the cellular surface prompts the suggestion that a reduced protein dosage might account for the enteric phenotype observed in these families (Figure 7 ). In agreement with this hypothesis is the demonstration that the major consequence of HSCR mutations located in various domains of the extracellular region of RET is a dramatic decrease of the plasma membrane expression of this receptor (Carlomagno et al., 1996; Iwashita et al., 1996; Pelet et al., 1998) . Following this model, the overall trophic signal transduced through RET encoded by the wildtype allele and by the low amount of RET Cys609 ,
RET
Cys618 or RET Cys620 dimer would not be sucient for the survival of enteric neurons (Figure 7 ). This scheme implies that unique mutations at Cys609, Cys618 or Cys620 are responsible for both MEN 2A and HSCR, and adequatly explains why the frequently occuring mutation at codon 634 is not found in individuals from these families. Interestingly, a similar genetic situation has already been documented by Iiri et al., (1994) who found that a unique mutation in the gene encoding the Gs a-subunit is gain of function in testicular Leydig cells and loss of function in the thyroid. However, the association of HSCR and MEN 2A appears to occur in 20 to 30% of families with mutations C618R or C620R (Mulligan et al., 1994b) , an observation that suggests that other genetic factors might in¯uence the expression of the enteric phenotype in these families. Missense mutations at codon 609 have also been described in two HSCR families with no evidence of endocrine neoplasia (Angrist et al., 1995; Mulligan et al., 1994b) and it has been recently showed that one of these two mutations which changes the cysteine for the bulky non polar amino acid tryptophan, leads to the almost complete disappearance of the 170 kDa RET product Pelet et al., 1998) . Therefore, it is conceivable that in certain circumstances, not only the position but also the nature of the mutation might contribute to the dysfunction of RET and act synergistically in determining the disease phenotype. While this work was being submitted for publication, Ito and coworkers reported on similar ®ndings, namely the impaired cell surface expression of RET with mutations at cysteines 609, 611, 618 and 620 .
In summary, we have shown that the activating capacity of mutations involving juxtamembrane cysteines of RET correlates with the MEN 2 disease phenotype. The present results further support that alterations of some of these cysteines exert a dual impact on RET, thus providing a possible explanation for the puzzling cosegregation of MEN 2A and HSCR in certain families. If this model is relevant in vivo, it follows that a unique mutation can be activating or inactivating depending on the tissue in which RET is expressed, a paradigm that might apply to other receptors involved in human diseases.
Materials and methods
Construction of retroviral expression vectors and production of ecotropic retroviruses
The cDNA coding for the 1114 aa isoform of RET (RET51) was obtained as previously detailed and subcloned in the retroviral vector pBabe Puro (Morgenstern and Land, 1990) . In this construct, the expression of the cDNAs encoding RET is driven by the Moloney Murine Leukaemia Virus (MoMuLV) 5' Long Terminal Repeat (LTR) promoter. The dierent MEN 2 mutations were introduced using the USE Mutagenesis Kit (Pharmacia Biotech) according to the manufacturer's instructions. The following oligonucleotides were used for mutagenesis:
C609R:
5'-GGCTATGGCACCCGCAACTGCTTCCCTGAG-3' C618R:
5'-GAGGAGGAGAAGCGCTTCTGCGAGCCCGAAG-3' C620R:
5'-GAGGAGAAGTGCTTCCGCGAGCCCGAAGAC-3'
C630R:
5'-ATCCAGGATCCACTGCGCGACGAGCTGTGCCGC-3' C634R:
5'-TGCGACGAGCTGCGCCGCACGGTGATCGCA-3'.
All mutations were-con®rmed by DNA sequencing. Additional RET mutants used in this study, M918T and V804L, have been previously described Pasini et al., 1997) .
Ecotropic retroviruses were obtained by transient transfection of the retroviral vectors into the BOSC 23 packaging cell line according to the protocol described by Pear et al. (1993) . Forty-eight hours after transfection, the supernatants were harvested and ®ltered on 0.45 mm pore size ®lters.
Titre of retroviruses was determined by infecting NIH3T3 cells in presence of 8 mg/ml of polybrene. Forty-eight hours after infection the cells were split 1 : 10 into medium containing 2 mg/ml puromycin. Puromycin resistant colonies were stained with Giemsa and counted on day 15. Retroviral titres were routinely comprised between 5610 5 and 1610 6 colony-forming units (cfu)/ml.
Cell culture, retroviral infections and transfections
NIH3T3 and BOSC 23 cell lines were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) and antibiotics. BOSC 23 cells were transfected using the CaPO 4 precipitation technique, as described by Pear et al. (1993) . For retroviral infections, 1610 6 NIH3T3 or Rat 1-cells were seeded on 100 mm culture plates. The day after, cells were incubated for 4 ± 7 h with 1610 6 infectious retroviral particles in presence of 8 mg/ml of polybrene. Forty-eight hours after infection, cells were trypsinized and seeded at a dilution of 1 : 10 in DMEM containing 2 mg/ml puromycin. Puromycin selection was carried on for about one week until the obtention of mass-selected populations. PC12 cells were grown in RPMI 1640 (Gibco BRL) supplemented with 10% horse serum and 5% FCS. For transient transfection assays, cells were plated at 3610 5 cells in 60 mm culture plates 24 ± 36 h prior to transfection. Transfection was performed using the lipofectin reagent following the manufacturer's instructions (Gibco BRL). All transfections were carried out with 2 mg of reporter plasmid (pvgf-CAT, pNGFI-A-CAT or RSVCAT) together with 2 mg of RET constructs. Variations in CAT activity between the dierent experiments were lower than 25% of the mean.
Transformation assays
Transfection of NIH3T3 cells and transformation assays were performed as previously described .
CAT assays
The pNGFI-A-CAT vector contains sequences from position 71150 to +200 of the NGFI-A promoter fused to the CAT gene (Jansenn-Timmen et al., 1989) . pvgf-CAT contains the vgf promoter, the 5' noncoding region and the ®rst methionine (from 7803 to +710) fused in-frame with the initiating methionine of the CAT gene (Possenti et al., 1992) . The pBLCAT2 and RSV-CAT vectors contain the CAT gene under the control of the HSV thymidine kinase promoter (position 7105 to +51) and of the Rous sarcoma virus promoter, respectively (Lukow and Schutz, 1987) . PC12 cells extracts were prepared 60 h after transfection, and CAT activity was analysed by thin-layer chromatography (TCL) with 95% chloroform-5% methanol, as described previously (Califano et al., 1995) . Each experimental point was cut from the TCL plate and counted. For each experiment, the percentage of conver-sion to the acetylated form of 14 C-chloramphenicol was then calculated. The results of at least three experiments, each made in duplicate, were plotted on an arbitrary scale as relative promoter induction.
Biotinylation of cell surface proteins
Cell surface proteins were biotinylated essentially as described by Asai et al. (1995) . Puromycin mass-selected NIH3T3 cells expressing the dierent RET alleles were grown to con¯uence in 100 mm culture dishes, then washed three times in biotinylation buer (10 mM HEPES [pH 8.8], 150 mM NaCl). Biotin N-hydroxysuccinimide ester (Biosys) dissolved in dimethyl sulfoxide, was added to the cells at a ®nal concentration of 150 mg/ml in 1 ml of biotinylation buer per dish. The reaction was incubated for 15 min at 208C, then stopped by the addition of TrisHCl (pH 7.4) to a ®nal concentration of 50 mM. Cells were then washed in 10 mM Tris-HCl (pH 7.4) containing 150 mM NaCl and pelleted.
RET protein analyses
RET protein immunoprecipitation and immunoblotting experiments were performed as described in Rossel et al., (1997) . Mass-selected NIH3T3 cells were lysed in lysis buer (20 mM Tris-HCl [pH 7.8], 150 mM NaCl, 1% Nonidet P-40, 2 mM EDTA), supplemented with a cocktail of proteases and phosphatase inhibitors (1 mM phenylmethylsulfonyl¯uoride [PMSF], 10 mg/ml aprotinin, 10 mg/ ml leupeptin, 10 mg/ml pepstatin, 1 mM sodium orthovanadate). Lysates were clari®ed by centrifugation and protein concentration was estimated by a modi®ed Bradford analysis (Bio-Rad). Comparable amounts of the dierent RET mutant proteins were immunoprecipitated for 3 h at 48C with an anti-RET rabbit polyclonal serum directed against the last 20 aa of the carboxyl terminus of the short RET isoform . Immune complexes were recovered by absorption on protein A coupled to sepharose beads (protein A Sepharose CL4B, Pharmacia), washed in lysis buer, resuspended in Laemmli buer (20 mM Tris-HCl [pH 6.8], 2%-SDS, 20% glycerol, 1.4 M of b-mercaptoethanol, 20 mg of bromophenol blue per ml), then subjected to SDS ± 7% PAGE and Western blotting as previously described . Immunoblots were ®rst probed with the monoclonal antiphosphotyrosine antibody 4G10 (UBI, NY, USA), incubated with an anti-mouse conjugated to horse-radish peroxidase (HRP) (Amersham, Les Ulis) and revealed with the Amersham ECL system, then stripped as described , reprobed with the anti-RET serum and revealed again using an anti-rabbit-HRP conjugate (Amersham, Les Ulis) and the ECL system. For the analysis of the disul®de-linked RET homodimer, cells were lysed in the lysis buer described above and 100 mg of total cellular proteins were fractionated under non reducing conditions on a SDS ± 7% polyacrylamide gel and Western blotted using previously described conditions .
For the detection of surface-expressed biotinylated RET proteins, equivalent amounts of the dierent RET mutant proteins were precipitated from total cellular lysates of surface-biotinylated cells with 30 ml of Immunopure immobilized streptavidin gel beads (Pierce). The resulting complexes were washed four times in lysis buer, then processed for SDS ± 7% PAGE and Western blotted as described above. Filters were ®rst probed with the anti-RET serum and revealed with an anti-rabbit-HRP conjugate (Amersham, Les Ulis) and the ECL system, then stripped, reprobed with a streptavidin-HRP conjugate (Amersham, Les Ulis) and revealed with the ECL system.
For in vitro kinase assays, mass-selected NIH3T3 cells were lysed in lysis buer supplemented with 10 mM iodoacetamide. Equivalent amounts of the dierent RET proteins were immunoprecipitated with the anti-RET serum and protein A coupled to sepharose beads (protein A Sepharose CL4B, Pharmacia). The resulting immunocomplexes were washed twice in lysis buer and twice in ice-cold immunokinase buer (50 mM HEPES pH 7.0, 5 mM MnCl 2 1 mM PMSF) then incubated for 10 min at room temperature in 30 ml of the same buer containing 4 mCi of [g 32 P]ATP (4500 Ci mmol 71 ICN) diluted with unlabeled ATP to a ®nal concentration of 26 pmol/sample. The reaction was stopped by addition of concentrated Laemmli buer without bmercaptoethanol. Proteins were boiled 5 min, then fractionated on a SDS ± 7% PAGE. 32 P-labeled bands were revealed by autoradiography of the dried gel and quanti®ed on an Imaging Densitometer GS 670 (Biorad).
